Josefa Alvarez-Fuentes

List of Publications by Year
in descending order

42 papers	939 citations	361413 20 h-index	454955 30 g-index
42 all docs	42 docs citations	42 times ranked	1233 citing authors

#	Article	IF	Citations
1	Receptor-targeted nanoparticles modulate cannabinoid anticancer activity through delayed cell internalization. Scientific Reports, 2022, 12, 1297.	3.3	13
2	Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases. Journal of Drug Delivery Science and Technology, 2017, 42, 84-93.	3.0	16
3	Peroral Polyester Drug Delivery Systems. , 2016, , 243-289.		0
4	Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucherâ€™s Disease. Current Medicinal Chemistry, 2016, 23, 929-952.	2.4	22
5	In vitro and in vivo evaluation of Î”9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. International Journal of Pharmaceutics, 2015, 487, 205-212.	5.2	44
6	Engineering of Î” 9 -tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids and Surfaces B: Biointerfaces, 2014, 123, 114-122.	5.0	23
7	Enhanced Cellular Uptake and Biodistribution of a Synthetic Cannabinoid Loaded in Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles. Journal of Biomedical Nanotechnology, 2014, 10, 1068-1079.	1.1	37
8	Drug Targeting to Cancer by Nanoparticles Surface Functionalized with Special Biomolecules. Current Medicinal Chemistry, 2012, 19, 3188-3195.	2.4	43
9	Use of Flow FocusingÂ® Technology to Produce Tobramycin-Loaded Plga Microparticles for Pulmonary Drug Delivery. Medicinal Chemistry, 2012, 8, 533-540.	1.5	6
10	Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. International Journal of Nanomedicine, 2012, 7, 5793.	6.7	39
11	Development and Validation of an RP-HPLC Method for CB13 Evaluation in Several PLGA Nanoparticle Systems. Scientific World Journal, The, 2012, 2012, 1-9.	2.1	8
12	Insulin-loaded PLGA microparticles: flow focusingversusdouble emulsion/solvent evaporation. Journal of Microencapsulation, 2011, 28, 430-441.	2.8	37
13	Nanostructures for Drug Delivery to the Brain. Current Medicinal Chemistry, 2011, 18, 5303-5321.	2.4	43
14	Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer. Current Drug Targets, 2011, 12, 1096-1111.	2.1	20
15	Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications. International Journal of Pharmaceutics, 2010, 393, 162-167.	5.2	3
16	Effectiveness of repeated administration of a new oral naltrexone controlled-release system on morphine analgesia. Journal of Pharmacy and Pharmacology, 2010, 53, 1201-1205.	2.4	2
17	Protein-loaded PLGA microparticles engineered by flow focusing: Physicochemical characterization and protein detection by reversed-phase HPLC. International Journal of Pharmaceutics, 2009, 380, 147-154.	5.2	28
18	Synthesis of lidocaine-loaded PLGA microparticles by flow focusing. International Journal of Pharmaceutics, 2008, 358, 27-35.	5.2	73

#	Article	IF	Citations
19	Development and in vitro evaluation of a controlled release formulation to produce wide dose interval morphine tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 544-549.	4.3	22
20	In vitro and in vivo Studies of a New Sustained Release Formulation of Morphine. Arzneimittelforschung, 2008, 58, 647-652.	0.4	0
21	Diclofenac Salts. III. Alkaline and Earth Alkaline Salts. Journal of Pharmaceutical Sciences, 2005, 94, 2416-2431.	3.3	15
22	Elaboration and â€œIn Vitroâ€•Characterization of 5-ASA Beads. Drug Development and Industrial Pharmacy, 2005, 31, 231-239.	2.0	18
23	In vitro evaluation of a morphine polymeric complex: Flowability behavior and dissolution study. AAPS PharmSciTech, 2004, 5, 23-29.	3.3	8
24	Development of Enteric-coated Timed-release Matrix Tablets for Colon Targeting. Journal of Drug Targeting, 2004, 12, 607-612.	4.4	43
25	EudragitÂ® RS-PM and EthocelÂ® 100 Premium: influence over the behavior of didanosine inert matrix system. Il Farmaco, 2002, 57, 649-656.	0.9	9
26	Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. International Journal of Pharmaceutics, 2002, 237, 107-118.	5.2	69
27	Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. International Journal of Pharmaceutics, 2002, 234, 213-221.	5.2	47
28	Diclofenac salts. I. fractal and thermal analysis of sodium and potassium diclofenac salts. Journal of Pharmaceutical Sciences, 2001, 90, 2049-2057.	3.3	46
29	Dehydration and rehydration of a hydrate diclofenac salt at room temperature. International Journal of Pharmaceutics, 1999, 181, 11-21.	5.2	4
30	Design of controlled release inert matrices of naltrexone hydrochloride based on percolation concepts. International Journal of Pharmaceutics, 1999, 181, 23-30.	5.2	32
31	Evaluation of EudragitÂ® RS-PO and EthocelÂ® 100 Matrices for the Controlled Release of Lobenzarit Disodium. Drug Development and Industrial Pharmacy, 1999, 25, 229-233.	2.0	20
32	Study of morphine hydrochloride percolation threshold in EudragitÂ® RSâ€“PM matrices. International Journal of Pharmaceutics, 1998, 170, 169-177.	5.2	21
33	Validation study of the conductometrical analysis. Application to the drug release studies from controlled release systems. Journal of Pharmaceutical and Biomedical Analysis, 1998, 18, 281-285.	2.8	10
34	Influence of the pH Value of the Dissolution Medium on the Release Profiles of a Morphine Polymeric Complex. Drug Development and Industrial Pharmacy, 1997, 23, 553-559.	2.0	3
35	Influence of the Disintegrant on the Drug Percolation Threshold in Tablets. Drug Development and Industrial Pharmacy, 1997, 23, 665-669.	2.0	0
36	Study of a complexation process between naltrexone and EudragitÂ® L as an oral controlled release system. International Journal of Pharmaceutics, 1997, 148, 219-230.	5.2	8

#	Article	IF	Citations
37	Preclinical study of a controlled release oral morphine system in rats. International Journal of Pharmaceutics, 1996, 139, 237-241.	5.2	9
38	Characterization of modified paracetamol by means of SEM and fractal analysis. International Journal of Pharmaceutics, 1996, 142, 143-151.	5.2	8
39	Physical characterization of carteolol: EudragitÂ® L binding interaction. International Journal of Pharmaceutics, 1995, 114, 13-21.	5.2	23
40	Influence of diluents and manufacturing method on the in vitro dissolution of carteolol hydrochloride matrix tablets. International Journal of Pharmaceutics, 1995, 118, 151-160.	5.2	22
41	Communications Simultaneous Hplc Determination of some Drugs Commonly Used in Cold Medications: Dextromethorphan, Dephenhydramine, Phenylephrine, Phenylpropanolamine and Pseudoephedrine. Drug Development and Industrial Pharmacy, 1995, 21, 605-613.	2.0	29
42	Morphine Polymeric Coprecipitates for Controlled Release: Elaboration and Characterization. Drug Development and Industrial Pharmacy, 1994, 20, 2409-2424.	2.0	16